tirzepatide fda approved weight loss approval for Zepbound: FSU researcher available for context on newly treatment BioCentury - Nov. 8 Quick

The NHS and NICE emphasise that weight management should be undertaken with professional guidance, particularly when prescription medicines are involved

Discuss all medications with your healthcare provider to identify potential interactions

Anders Fink-Jensen at Copenhagen University Hospital and including NIH scientists, studied the effects and safety of the GLP-1 semaglutide in people seeking treatment for AUD who also had obesity

For individuals with Type 2 diabetes, who are at an increased risk for heart disease, GLP-1 therapy has been shown to lower the risk of heart attack, stroke, and other cardiovascular events

This is what we talked about on today's episode of the GLP1 Hub podcast

Healthcare Challenges Healthcare facilities in Philadelphia face increased demands related to obesity-related health issues, such as type 2 diabetes, heart disease, and joint problems